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 ABSTRACT  
As part of our interest into the bioinorganic chemistry of gallium, gallium(III) complexes 
of the azole ligands 2,1,3-benzothiadiazole (btd), 1,2,3-benzotriazole (btaH) and 1-
methyl-4,5-diphenylimidazole (L) have been isolated. Reaction of btaH or btd with 
GaBr3 or GaCl3 resulted in the mononuclear complexes [GaBr3(btaH)2] (1) and 
[GaCl3(btd)2] (2), respectively, while treatment of GaCl3 with L resulted in the anionic 
complex (LH)2[GaCl4]Cl (3). All three complexes were characterized by single-crystal 
X-ray crystallography and IR spectroscopy, while their antiproliferative activities were 
investigated against a series of human and mouse cancer cell lines. 
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 1. Introduction 
 
The coordination chemistry of gallium(III) has became an area of increasing 
research activity due to its relevance of both materials science [1] and biomedical 
developments [2]. In the area of materials science, for example, complex [Ga2(saph)2q2], 
where saph2- is the Schiff-base ligand bis(salicylidene-o-aminophenolate)(-2) and q- is 8-
quinolinate(-1), is a very good candidate as a novel electron-transporting and emitting 
material for organic light-emitting diodes (OLEDs) [1d]. [Gaq3] is also a promising 
electroluminescence (EL) material, exhibiting higher power efficiency than the aluminum 
analog, [Alq3] [1e,1f]. The biological interest of gallium(III) complexes originates from 
the incorporation of gallium(III) radionuclides (67Ga3+, 68Ga3+) into diagnostic 
radiopharmaceuticals [2a]. In addition, the gallium salts GaCl3 and Ga(NO3)3 as well as 
few gallium(III) complexes [2b-2m] have exhibited antitumour activity, while Ga(NO3)3 
and some GaCl3/L complexes (L = various azoles) showed in vitro anti-HIV (HIV = 
human  immunodeficiency virus) activity [2n]. The biological activity of gallium(III) 
complexes has often been attributed to the fact that gallium(III) is the diamagnetic 
biological mimic of iron(III) [2o]. It is worth mentioning that [Gaq3], which is of current 
interest in materials science [1e,1f], is also being evaluated in clinical trials, along with 
other Ga(III) complexes, such as gallium maltolate [tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III)], for anticancer activity [3]. 
Following our interest in the coordination chemistry of gallium(III) [4] which is 
focused on the synthesis, structural characterization, physical/spectroscopic study and 
evaluation of the biological (antitumour and antiviral) activity of Ga(III) complexes with 
biologically relevant and non-relevant ligands, we report herein the synthesis, structural 
characterization and antiproliferative activity of three gallium complexes based on the 
azole ligands 2,1,3-benzothiadiazole (btd), 1,2,3-benzotriazole (btaH) and 1-methyl-4,5-
diphenylimidazole (L). 
 
 
 
 2. Experimental 
 
2.1. Reagents and physical measurements 
 
All manipulations were performed under a dinitrogen atmosphere, using standard 
inert atmosphere techniques and purified solvents unless otherwise noted. All other 
chemicals were purchased from commercial sources and used without further 
purification. L was synthesized as described elsewhere [5]. Microanalyses (C, H and N) 
were performed by the University of Ioannina Microanalytical Laboratory using an EA 
1108 Carlo Erba analyzer. IR spectra (4000-450 cm-1) were recorded on a Perkin-Elmer 
16 PC spectrometer with samples prepared as KBr pellets. Far-IR spectra (500-50 cm-1) 
were recorded on a Bruker IFS 113v FT spectrometer as polyethylene pellets. 
 
2.2. Compound preparation 
 
2.2.1. Preparation of [GaBr3(btaH)2] (1) 
A solution of GaBr3 (0.3 g, 0.9 mmol) in 3 ml of toluene diethyl/ether (80:20, v/v) 
was added dropwise to a stirred solution of btaH (0.3 g, 2.5 mmol) in toluene (20 ml). 
The resultant solution was refluxed for about 3 hours and then left undisturbed at room 
temperature. Upon standing, X-ray quality colorless crystals of 1 formed over a period of 
3 days. The crystals were collected by filtration, washed with toluene and dried in 
vacuum. Yield: 0.31 g (63%); Anal. Calc. for C12H10N6Br3Ga: C, 26.32; H, 1.84; N, 
15.34. Found: C, 26.28; H, 1.82; N, 15.33%. Selected IR data (cm-1): 3238 m [ν(N-H)], 
1222 mb [ν(N=N)], 1116 s [ν(N-N)], 291s [ν(Ga-Br)] and 224w [ν(Ga-N)]. 
 
2.2.2. Preparation of [GaCl3(btd)2] (2) 
A solution of GaCl3 (0.25 g, 1.40 mmol) in 5 ml of toluene/diethyl ether (80:20, 
v/v) was added dropwise to a stirred solution of btd (0.6 g, 4.4 mmol) in toluene diethyl 
ether (60:40, v/v) (10 ml). The resultant solution was refluxed for about 2 hours and then 
left undisturbed at -10 °C. Upon standing at low temperature for several days, X-ray 
quality yellowish crystals of 2 formed. The crystals were collected by filtration, washed 
with diethyl ether and dried in vacuum. Yield: 0.60 g (95%); m.p.: 112°C. Anal. Calc. for 
C12H8N4S2Cl3Ga: C, 32.14; H, 1.80; N, 12.49. Found: C, 32.13; H, 1.78; N, 12.49%. 
Selected IR data (cm-1): 1612 s and 1528 s [ν(C=C)], 1482 s [ν(C=N)], 961 m and 922 s 
[ν(S-N)], 382s [ν(Ga-Cl)] and 207w [ν(Ga-N)]. 
 
2.2.2. Preparation of (LH)2[GaCl4]Cl (3) 
A solution of GaCl3 (0.2 g, 1.13 mmol) in 5 ml of toluene diethyl/ether (80:20, 
v/v) was added dropwise to a stirred mixture of L (0.6 g, 2.6 mmol) in diethyl ether (1 
ml). The resultant mixture was stirred until a clear yellowish solution was obtained. Slow 
evaporation of the resultant solution afforded a microcrystalline solid. The solid was 
collected by filtration, washed with toluene and diethyl ether, and dried in vacuum. The 
product was recrystallised three times from toluene to give crystals of 3 suitable for X-ray 
structural analysis. The crystals were collected by filtration, washed with toluene and 
dried in vacuum. Yield: 0.18 g (45%); Anal. Calc. for C32H30N4Cl5Ga: C, 53.56; H, 4.21; 
N, 7.81. Found: C, 53.36; H, 4.17; N, 7.78%. Selected IR data (cm-1): 3146-2620 sb 
[ν(N-H)], 1622 m [ν(C=N)], 1578 w [ν(C=C)] and 369s [ν(Ga-Cl)]. 
 
2.3. Single-crystal X-ray crystallography 
 
Crystals of 1 and 2 were mounted in air, while crystals of 3 were mounted in air 
and covered with epoxy glue. Diffraction measurements for 1 and 2 were made on a 
Crystal Logic Dual Goniometer diffractometer using graphite-monochromated Mo 
radiation, while those for 3 were made on a P21 Nicolet diffractometer using graphite-
monochromated Cu radiation. Complete crystal data and parameters for data collection 
and processing are reported in Table 1. Unit cell dimensions were determined and refined 
by using the angular settings of 25 automatically centred reflections in the ranges 11 < 2θ  
< 23° for 1 and 2 and 22 < 2θ < 54° for 3. Three standard reflections monitoring every 97 
reflections showed less than 3% variation and no decay. Lorentz, polarization and ψ-scan 
(only for 1) corrections were applied using CRYSTAL LOGIC software. The structures 
were solved by direct methods using SHELXS-86 [6a] and refined by full-matrix least 
squares techniques on F2 with SHELXL-97 [6b]. All hydrogen atoms were located by 
difference maps and refined isotropically, except those on the methyl groups of 3 which 
were introduced at calculated positions as riding on bonded atoms. For all the three 
structures, all non-hydrogen atoms were refined using anisotropic thermal parameters. 
 
2.4. In vitro cytotoxic activity 
 
2.4.1. Test substances 
All test substances (complexes 1, 2 and 3) were diluted in methanol at a 
concentration of 200 mM. Final concentration of methanol in culture was always less 
than 0.5%, a concentration that produced no effects on cell growth and proliferation, as 
was experimentally confirmed. 
 
2.4.2. Cell lines 
Cell lines used were HeLa [7] (human cervical cancer), OAW-42 [8] (human 
ovarian cancer), HT29 [9] (human colon cancer), MCF-7 [10] (human breast cancer), 
T47D [11] (human breast cancer), and L929 (929 is a clone isolated [12] from the 
parental strain L derived from normal subcutaneous areolar and adipose tissues of a 
mouse [13]). Cells were grown as monolayer cultures in T-75 flasks (Costar), were 
subcultured twice a week at 37°C in an atmosphere containing 5% CO2 in air and 100% 
relative humidity. Culture medium used was Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco Glasgow, UK), supplemented with 10% Fetal Bovine Serum (FBS, 
Gibco, Glasgow, UK), 100 µg/ml streptomycin and 100 IU/ml penicillin. 
 
2.4.3. Cell growth and proliferation assays 
Adherent cells at a logarithmic growth phase were detached by addition of 2-3 ml 
of a 0.05% trypsin (Gibco, 1:250) - 0.02% EDTA mixture and incubation for 2-5 min at 
37°C. Cells were plated (100 µl per well) in 96-well flat-bottom microtiter plates (Costar-
Corning, Cambridge) at a density of 5,000 (HeLa and L929) or 10,000 (HT-29, OAW-42, 
MCF-7 and T47D) cells per well. Cells were left for 24 h at 37°C to resume exponential 
growth. An equal volume (100 µl) of either complete culture medium (control wells), or 
twice the final substance concentration diluted in complete culture medium, was added 
24 h later. Six replicate wells for each concentration were used for the sulforhodamine B 
(SRB) assay and three replicate wells for the bromodeoxyuridine (BrdU) assay. 
Background control wells (n=8), containing the same volume of complete culture 
medium, were included in each experiment. Cell growth or DNA-synthesis was evaluated 
48 h later by means of the SRB or BrdU assays. All experiments were performed at least 
twice. 
 
2.4.4. SRB assay 
The SRB assay was carried out by a modification [14] of the previously reported 
method [15]. In brief, culture medium was aspirated prior to fixation using a microplate-
multiwash device (Tri-Continent Scientific, Inc. Grass Valley, CA) and 50 µl of 10% 
cold (4°C) TCA were gently added to the wells. Microplates were left for 30 min at 4°C, 
washed 5 times with deionized water and left to dry at room temperature for at least 24 
hr. Subsequently, 70 µl 0.4% (w/v) sulforhodamine B (Sigma) in 1% acetic acid solution 
were added to each well and left at room temperature for 20 min. SRB was removed and 
the plates were washed 5 times with 1% acetic acid before air drying. Bound SRB was 
solubilized with 200 µl 10 mM unbuffered Tris-base solution (E. Merck, Darmstadt, 
Germany) and plates were left on a plate shaker for at least 10 min. Absorbance was read 
in a 96-well plate reader (Anthos-2001, Anthos labteck instruments, A-5022, Salzburg) at 
492 nm subtracting the background measurement at 620 nm. The test optical density 
(OD) value was defined as the absorbance of each individual well, minus the blank value 
(“blank” is the mean optical density of the background control wells, n=8). Mean values 
and CV from six replicate wells were calculated automatically. Results were expressed as 
the “survival fraction” (sf), derived from the following equation: sf = ODx / ODc, (where 
ODx and ODc represent the test and the control optical density respectively).  
 
2.4.5. BrdU assay 
DNA-synthesis was estimated by the BrdU assay [16] using a standard 
colorimetric ELISA (Boehringer Mannheim). After 47 h exposure to test substances, cells 
were incubated at 37°C for further 60 min in the presence of 10 µM BrdU. Subsequently, 
cells were fixed with an ethanol-containing fixative, an anti-BrdU mouse monoclonal 
antibody conjugated with peroxidase was added and plates were incubated at 37°C for 60 
min. After washing, peroxidase substrate (tetramethylbenzidine) was added, the reaction 
was stopped 10 min later by 1 M H2SO4 and absorbance was read at 450 nm subtracting 
the background measurement at 620 nm. Results from each triplicate well 
(ODBrdUx/ODBrdUc) were divided by the results of a parallel experiment estimated 
with the SRB assay (ODSRBx/ODSRBc) and they were expressed as the "DNA synthesis 
fraction" (fDNA) [derived from the following equation: fDNA = (ODBrdUx × ODSRBc) 
/ (ODBrdUc × ODSRBx), where ODx and ODc represent the test and the control optical 
density respectively], resulting in an estimation of the DNA synthesis per cell number.  
 
2.4.6. Cell cycle analysis by flow cytometry 
For cell cycle experiments 1.5 × 106  (HeLa and L929) or 2.5 × 106  (HT-29, 
OAW-42, MCF-7 and T47D) cells were seeded in 75 cm2 flasks and left for 24 h in 
incubator to resume exponential growth. Cells were exposed to test substances (at 
concentrations that  produced 50% inhibition of cell growth - estimated by the SRB 
assay) and after 48 h they were harvested (using trypsin/EDTA as above), washed in PBS 
and counted in a hemocytometer chamber; 3 × 106 cells were resuspended in 125 µl cold 
"Saline GM" (g/L: glucose 1.1; NaCl 8.0; KCl 0.4; Na2HPO4·12H2O 0.39; KH2PO4 0.15; 
and 0.5 mM EDTA) followed by the addition of 375 µl of 95% non-denatured, ice-cold 
ethanol [17]. Cells were kept in 4°C for a maximum period of 3 days (short-term storage 
does not alter results, as was experimentally confirmed) until analysis was performed. 
For cell cycle analysis a 10% of standard chicken erythrocyte nuclei were added 
as a control. The samples were processed in a DNA-preparation Epics Workstation 
(Coulter, El). By this method the content of cellular DNA is assessed using Propidium 
Iodide [18,19]. To avoid an increased signal by staining artifact on double stranded RNA, 
cells were digested with DNase-free RNase A [20]. 
Cellular DNA content was measured using an Epics II flow cytometer (Coulter, 
El). The fluorescent signals from 10,000-20,000 cells were collected and the result was 
displayed as a frequency-distribution histogram (DNA histogram). The mean channel, 
cell count, standard deviation (SD), coefficient of variation (CV), DNA index (DI) and 
cell cycle distribution were calculated for each sample using the Multicycle Cell Cycle 
Analysis Software (Phoenix Flow Systems Inc.). Care was taken to exclude any doublets 
or cell debris noise from the assessment. 
 
3. Results and Discussion 
 
3.1. Brief synthetic comments 
  
Complexes 1 and 2 were prepared by the simple reactions of GaBr3 or GaCl3 and btaH or 
btd in toluene/diethyl ether under nitrogen employing 1:3 molar ratios, respectively. A 
similar reaction involving GaCl3 and btaH has yielded [GaCl3(btaH)2] [4a]. An 1:1 
complex of GaCl3/btaH has also been isolated and structurally characterized [4a]. An 
attempt to isolate the 1:1 GaBr3/btaH complex was unsuccessful resulting in 1 in a lower 
yield. Complex 2 is also the only product resulting from the GaCl3/btd reaction mixtures 
in various molar ratios. Complex 3 might be regarded as a product of hydrolysis which is 
pretty usual in Ga(III) chemistry in water or water containing solutions [4f]. 
 
3.2. IR spectra 
 
The IR spectrum of 1 exhibits a medium intensity band at ~3238 cm-1, assignable 
to ν(N-H). The bands at 1222 and 1116 cm-1 are attributed to the ν(N=N) and ν(N-N) 
vibrations, respectively, and are shifted to higher wavenumbers with respect to the 
spectrum of the free ligand [1208 vs and 1084 m, respectively]. The IR spectrum of 2 
exhibits three strong intensity bands at 1612, 1528 and 1482 cm-1 assignable to stretching 
carbon-carbon and carbon-nitrogen vibrations. These bands are not shifted significantly 
with respect to the spectrum of the free ligand [1608 w, 1518 s and 1476 s]. The bands at 
950 and 916 cm-1 in the spectrum of btd, which are assigned to the ν(S-N) mode, have 
been shifted to higher wavenumbers in the spectrum of 2 [961 and 922 cm-1]. A set of 
broad bands in the region of 3146-2620 cm-1 in the spectrum of 3 can be assigned to the 
ν(N-H) of the protonated ligand, LH+. The ν(C=N) and ν(C=C) of the free L at 1602 and 
1575 cm-1 have shifted to 1622 and 1578 cm-1 in the spectrum of 3 due to protonation. 
The far-IR spectra of all three complexes are expected to show one Ga-X (X = Cl 
or Br) stretching mode [4a] and these  modes appear at 291s [ν(Ga-Br) in 1], 382s [ν(Ga-
Cl) in 2] and 369s [ν(Ga-Cl) in 3]. The far-IR spectra of complexes 1 and 2 exhibit one 
more band at 224 and 207 cm-1, respectively, which are attributed to the ν(Ga-N) mode 
[4a]. 
 
3.3. Description of structures 
 
An ORTEP diagram of 1 is shown in Fig. 1. Selected bond distances and angles 
are given in Table 2. Complex 1 is isostructural with [GaCl3(btaH)2] [4a]. Its structure 
consists of the monomeric discrete [GaBr3(btaH)2] units. The gallium coordination 
geometry is trigonalbipyramidal with the bromo ligands defining the equatorial plane. 
There is a two-fold crystallographic axis along the Ga-Br2 bond. The Ga-N bond length 
in complex 1 [2.212(3) Å] is longer than that of [GaCl3(btaH)2] [2.169(2) Å]. The 
dihedral angle between the best planes of the btaH molecules is 10.90 Å and is larger 
than that of [GaCl3(btaH)2] [7.4°]. The N1 proton is hydrogen bonded to atom Br1 of a 
neighboring molecule [N1···Br1’ (1-x, -y, 1-z) 3.425(4) Å, HN1···Br1’ 2.64(7) Å and N1-
HN1···Br1’ 149(6)°] creating a hydrogen-bonded tape running parallel to the a axis (Fig. 
2). These tapes are hold together in the crystal lattice through π-π interactions. Those 
interactions form between the phenyl groups of the coordinated btaH molecules of 
neighboring tapes [centroid···centroid’ (1-x, 0.5+y, 1.5-z) 3.658(4) and 3.906(4) Å] (Fig. 
2). 
Complex 2 crystallizes in the monoclinic space group C2/c. An ORTEP diagram 
of 2 is shown in Fig. 3, while selected bond distances and angles are listed in Table 3. Its 
structure consists of monomeric discrete [GaCl3(btd)2] units. The gallium coordination 
geometry is again trigonalbipyramidal with the choro ligands defining the equatorial 
plane. There is a two-fold crystallographic axis along the Ga-Cl1 bond. The Ga-Cl bond 
lengths in complex 2 [2.171(2) and 2.180(1) Å] compare favourably with those of 
[GaCl3(btaH)2] [2.204(1) and 2.178(2) Å]. The Ga-N bond length in complex 2 [2.201(3) 
Å] is longer than that of [GaCl3(btaH)2] [2.169(2) Å], but compares well with that of 1 
[2.212(3) Å]. The dihedral angle between the best planes of the btd molecules is 52.51 Å 
and is much larger than that of 1 and [GaCl3(btaH)2] [10.90 and 7.4°, respectively]. There 
appear to be intermolecular stacking interactions between the nearly parallel btd ligands. 
Those interactions involve both the thiadiazole and the phenyl groups of the btd ligands 
as shown in Fig. 4. 
An ORTEP diagram of the asymmetric unit of 3 is shown in Fig. 5. Selected bond 
distances and angles are listed in Table 4. The crystal of 3 consists of protonated LH+ 
ligand cations, tetrachlorogallate(III) anions and Cl- anions. The Ga-Cl distances in the 
tetrahedral [GaCl4]- ion are in the narrow range 2.152(1)-2.173(1) A ˚ with the Cl-Ga-Cl 
angles varying from 107.1(1)° to 110.9(1)°. These values are similar to those observed 
for other complexes containing the tetrachlorogallate(-1) ion [2g,4e]. The crystal 
structure of (LH)2[GaCl4]Cl is dominated by an intermixture of N-H···Cl and CMe-H···π 
hydrogen bonds, Ga-Cl···πazole and π-π interactions (Fig. 6). The organic moieties LH+ are 
connected through N-H···Cl and C-H···πphenyl interactions to form a chain; data are as 
follows N3···Cl5’ (2-x, -y, 2-z) 3.088(3) Å, HN3···Cl5’ 2.24(4) Å and N3-HN3···Cl5’ 
160(4)°; N13···Cl5’’ (x-1, 1+y, z-1) 3.066(4) Å, HN13···Cl5’’ 2.19(5) Å and N13-
HN13···Cl5’’ 177(5)°; C38···Centroid’ (1-x, -y, 2-z) 3.691(5) Å, H38A···Centroid’ 
2.85(1) Å and C38-H38A···Centroid’ 147(1)°. The organic chains are bridged through 
Ga-Cl···πazole interactions to form layers [Cl1···Centroid’’ (-x, 1-y, 1-z) 3.455(2) Å and 
Cl4···Centroid’’’ (1-x, 1-y, 1-z) 3.550(2) Å], which are further bridged through π-π 
interactions in the third dimension [centroid···centroid’ (1-x, -y, 2-z) 3.778(3) and 
centroid···centroid’’’’ (-x, 2-y, 1-z) 3.878(3)]. 
 
3.4. Antiproliferative activity 
 
Complexes 1 (Fig. 7) and 2 (Fig. 8) had no significant inhibition on cellular 
proliferation against HeLa, HT29 and OAW-42 cancer cell lines and a small effect 
against L929 normal fibroblastic cell line. In contrast, complex 3 inhibited cellular 
growth of all cell lines, with IC50 concentrations varying between 75 and 125 µM (Fig. 
9). 
DNA synthesis was not inhibited in HT29, HeLa, MCF-7 or L929 cell lines when 
they were exposed to 3 at concentrations up to 100 µM. Higher concentrations exhibited 
an inhibition of DNA synthesis per cell number only in HeLa and at a lower level in 
L929 cells (Fig. 10). 
Treatment with IC50 concentrations of 3 for 48 h had no effects on cell cycle 
distribution of HeLa and T47D cells (Table 5). HT29 and MCF-7 were partially arrested 
at the G1 phase, OAW-42 were arrested at the G1 phase with a percentage of 87.2% and 
L929 fibroblasts exhibited a partial G2-phase arrest. However, the overall effect of 3 on 
cell cycle distribution (except with OAW-42 cells) was not significant, an observation in 
concert with the results of the BrdU assay, where no inhibition of DNA-synthesis was 
observed. 
 
4. Concluding comments 
 
In this study, three gallium(III) azole complexes were synthesized and structurally 
characterized, while their antiproliferative activities were studied. The three different 
azole ligands were chosen in order to be able to draw structure-properties relations. In 
two of the complexes (1 and 2) the Ga(III) atom is in a trigonal-bipyramidal coordination 
environment where the terminal azole ligands occupy the axial positions. The third 
complex (3) consists of [GaCl4]- anions, chlorine anions and  protonated imidazole 
cations. From the three complexes tested only 3 exhibited a potent anti-proliferative 
activity against all cell lines tested. The order of cell lines in respect to their sensitivity to 
3 (at IC50 values) is as follows: HeLa > MCF-7 > T47D > L929 > HT29 > OAW-42. 
Complex 3 does not inhibit DNA synthesis at concentrations that exert antiproliferative 
activity (IC50s) and does not produce major disturbances in cell cycle distribution (with 
the exception of OAW-42 cells that, notably, are the most resistant to its anti-proliferative 
activity). 
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Appendix A. Supplementary data 
 
CCDC  717554, 717555, and 717553 contain the supplementary crystallographic 
data for 1, 2, and 3. These data can be obtained free of charge from the Cambridge 
Crystallographic Data Center via http://www.ccdc.cam.ac.uk/data_request/cif. 
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Fig. 1. A labeled ORTEP plot of [GaBr3(btaH)2] (1) showing 30 % probability ellipsoids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. The hydrogen-bonded tape of [GaBr3(btaH)2] (1) running parallel to a axis 
(above) and the stacking of the tapes (below). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. A labeled ORTEP plot of [GaCl3(btd)2] (2) showing 30 % probability ellipsoids.  
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Fig. 4. The stacking of the [GaCl3(btd)2] molecules in 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. A labeled ORTEP plot of the asymmetric unit of (LH)2[GaCl4]Cl (3), showing 30 
% probability ellipsoids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. The intermixture of the weak interactions between the anions and the cations in 3. 
Most of the hydrogen atoms have been omitted for clarity. 
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Fig. 7. Dose-effect plots of complex 1 against a panel of human and mouse cancer cell 
lines 24 h after the administration of the agents. Cytotoxicity was estimated via SRB 
assay (each point represents a mean of six replicate wells). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Dose-effect plots of complex 2 against a panel of human and mouse cancer cell 
lines 24 h after the administration of the agents. Cytotoxicity was estimated via SRB 
assay (each point represents a mean of six replicate wells). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Dose-effect plots of complex 3 against a panel of human and mouse cancer cell 
lines 24 h after the administration of the agents. Cytotoxicity was estimated via SRB 
assay (each point represents a mean of six replicate wells). 
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Fig. 10. DNA synthesis inhibition of human and mouse cancer cell lines 48 h after the 
administration of complex 3. 
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Table 1 
Crystallographic data for complexes [GaBr3(btaH)2] (1), [GaCl3(btd)2] (2) and 
(LH)2[GaCl4]Cl (3). 
 1 2 3 
Empirical formula C12H10N6Br3Ga C12H8N4S2Cl3Ga C32H30N4Cl5Ga 
Formula weight 547.68 448.42 717.60 
Crystal colour, habit Colourless, prism Colourless, prism Colourless, prism 
Crystal dimensions (mm) 0.15 × 0.25 × 0.40 0.20 × 0.25 × 0.40 0.15 × 0.15 × 0.35 
Crystal system Monoclinic Monoclinic Triclinic 
Space group I2/a C2/c P-1 
a (Å) 16.797(10) 12.098(11) 10.2358(10) 
b (Å) 7.058(4) 7.525(6) 14.9649(16) 
c (Å) 14.276(9) 18.968(16) 12.2350(11) 
α (º) 90 90 69.235(4) 
β (º) 106.60(2) 107.65(3) 86.879(3) 
γ (º) 90 90 74.939(4) 
V (Å3) 1621.9(17) 1646(2) 1690.7(3) 
Z 4 4 2 
Dcalc (g/cm-3) 2.243 1.810 1.410 
F(000) 1040 888 732 
µ (mm-1) 9.091 2.411 4.966 
Radiation (λ, Å) 0.71073 0.71073 1.54180 
Temperature (K) 298 298 298 
a Defined as: R1 = Σ(|Fo| - |Fc|) ⁄ Σ(|Fo|), wR2 = { Σ[w(Fo2 – Fc2)] ⁄ Σ[w(Fo2)2]}½, where 
w=1 ⁄ [ σ2(Fo2) + (aP)2 + (bP)] with P = [max (Fo2, 0) +2Fc2] ⁄ 3. 
 
 
 
Scan mode θ - 2θ θ - 2θ θ - 2θ 
Scan speed (º min-1) 3.5 4.2 4.5 
Scan range (º) 2.3 + α1 α2 separation 2.4 + α1 α2 separation 2.25 + α1 α2 separation 
θ range (º) 2.53 – 25.00 2.25 - 24.99 3.67 - 61.97 
hkl ranges 0 to 19 
0 to 8 
-16 to 16 
-14 to 13 
-8 to 0 
0 to 22  
-10 to 9 
-14 to 17 
0 to 14 
Reflections collected 1486 1499 4586 
Independent reflections(Rint) 1430 (0.0250) 1450 (0.0219) 4368 (0.0149) 
No of refined parameters 121 118 479 
Observed reflections 
[I>2σ (I)] 
1293 1341 3740 
    
GOF (on F2) 1.143 1.062 1.087 
Final R indices a[I>2σ (I)]  R1 = 0.0332 
wR2 = 0.0903 
R1 = 0.0301 
wR2 = 0.0826 
R1 = 0.0345 
wR2 = 0.0830 
R indices a(all data)  R1 = 0.0375 
wR2 = 0.0930 
R1 = 0.0333 
wR2 = 0.0852 
R1 = 0.0448 
wR2 = 0.1009 
Largest difference 
peak and hole (e Å-3) 
0.681 and -1.263 0.546 and -0.387 0.418 and -0.493 
Table 2 
Selected interatomic distances (Ǻ) and angles (o) for complex 1 
Ga-N(3)’  2.212(3)   N(3)-N(2)  1.314(5) 
Ga-N(3) 2.212(3)   N(3)-C(8) 1.378(6) 
Ga-Br(2) 2.3204(17) N(1)-N(2) 1.323(5) 
Ga-Br(1)’ 2.3436(11) N(1)-C(9) 1.344(6) 
Ga-Br(1) 2.3436(11) N(1)-HN1 0.89(7)  
    
N(3)’-Ga-N(3)   176.2(2)   Br(2)-Ga-Br(1)’ 123.81(3)  
N(3)’-Ga-Br(2) 88.08(10) N(3)’-Ga-Br(1)  90.13(10) 
N(3)-Ga-Br(2) 88.08(10) N(3)-Ga-Br(1)  92.01(10) 
N(3)’-Ga-Br(1)’ 92.01(10) Br(2)-Ga-Br(1) 123.81(3)  
N(3)-Ga-Br(1)’ 90.13(10) Br(1)’-Ga-Br(1) 112.39(6)  
 
(’) Symmetry code: -x+1/2,y,-z+1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Selected interatomic distances (Ǻ) and angles (o) for complex 2. 
Ga-Cl(1) 2.171(2)   N(3)-C(8) 1.357(4) 
Ga-Cl(2)’ 2.180(1) N(3)-S(2) 1.631(3) 
Ga-Cl(2) 2.180(1) S(2)-N(1) 1.601(3) 
Ga-N(3) 2.201(3)   N(1)-C(9) 1.336(5) 
Ga-N(3)’ 2.201(3)     
    
Cl(1)-Ga-Cl(2)’ 120.24(4) Cl(2)’-Ga-N(3)’     88.34(9)  
Cl(1)-Ga-Cl(2) 120.24(4) Cl(2)-Ga-N(3)’  90.45(9)  
Cl(2)’-Ga-Cl(2) 119.52(7) N(3)-Ga-N(3)’ 177.58(12) 
Cl(1)-Ga-N(3)  91.21(6) C(8)-N(3)-S(2) 107.52(19) 
Cl(2)’-Ga-N(3)  90.45(9) C(8)-N(3)-Ga 130.00(19) 
Cl(2)-Ga-N(3)  88.34(9) S(2)-N(3)-Ga 122.41(14) 
Cl(1)-Ga-N(3)’  91.21(6) N(1)-S(2)-N(3)  99.20(15) 
 
(’) Symmetry code: -x+1,y,-z+1/2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
Selected interatomic distances (Ǻ) and angles (o) for complex 3. 
Ga-Cl(3)  2.152(1) C(2)-N(3) 1.309(5) 
Ga-Cl(4) 2.166(1) N(3)-C(4) 1.389(4) 
Ga-Cl(1) 2.171(1) N(11)-C(22) 1.320(5) 
Ga-Cl(2) 2.173(1) N(11)-C(25) 1.392(4) 
N(1)-C(2) 1.320(5) N(11)-C(38) 1.463(4) 
N(1)-C(5) 1.393(4) C(22)-N(13) 1.318(5) 
N(1)-C(18) 1.460(4) N(13)-C(24) 1.383(4) 
    
Cl(3)-Ga-Cl(4) 110.87(5) Cl(3)-Ga-Cl(2) 110.55(5) 
Cl(3)-Ga-Cl(1) 110.17(5) Cl(4)-Ga-Cl(2) 108.62(5) 
Cl(4)-Ga-Cl(1) 109.49(5) Cl(1)-Ga-Cl(2) 107.05(5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 
Cell cycle distribution of cells before (control) and after 48 h exposure to IC50 values of 3 
as determined by flow cytometry. 
  G1 (%) S (%) G2 (%) 
HeLa Control 62.0 26.6 11.4 
 3 57.7 35.0 7.3 
T47D Control 57.4 28.4 14.3 
 3 58.1 34.3 7.6 
HT29 Control 43.5 39.4 17.1 
 3 53.2 24.6 22.2 
MCF-7 Control 42.0 50.4 7.6 
 3 54.1 35.4 10.5 
OAW-42 Control 47.8 11.3 40.9 
 3 87.2 11.8 1.0 
L929 Control 42.0 48.0 10.0 
 3 43.0 23.6 33.4 
 
 
